Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 5/20 | 0.80 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.43 |
| ▸ | GRM5 | P41594 | 2/20 | 0.42 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.37 |
| ▸ | KMO | O15229 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1437079 | 0.91 | MDM2 (0.66) | MDM2GRM5PDE4BPDE4DKMO | |
| SCHEMBL1443425 | 0.89 | MDM2 (1.00) | MDM2PIN1GRM5PTGER4PKM | |
| SCHEMBL9893992 | 0.88 | MDM2 (0.62) | MDM2GRM5MAPT | |
| SCHEMBL1437217 | 0.88 | MDM2 (0.80) | MDM2PIN1GRM5PDE4BPDE4D | |
| SCHEMBL9893927 | 0.86 | MDM2 (1.00) | MDM2PIN1GRM5PTGER4PKM | |
| SCHEMBL1436973 | 0.86 | MDM2 (0.89) | MDM2PIN1GRM5PTGER4PKM | |
| SCHEMBL9893679 | 0.86 | MDM2 (0.79) | MDM2PIN1GRM5PKMKDM4C | |
| SCHEMBL1437248 | 0.86 | MDM2 (0.59) | MDM2PDE4BPDE4DPKMSORT1 | |
| SCHEMBL1437137 | 0.85 | MDM2 (0.87) | MDM2PIN1GRM5PTGER4PDE4B | |
| SCHEMBL27862799 | 0.84 | MDM2 (0.85) | MDM2PIN1PTGER4PKMATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102574785-A | Tetra-substituted heteroaryl compounds and their use as MDM2 and/or MDM4 modulators | NOVARTIS AG | 2012-07-11 | — | — | CN | disclosed |
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | NOVARTIS AG (CH) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | MDM4, MDM2, TP53 | MDM2 2/4885PIN1 844/4885GRM5 3019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.